The PI3K/Akt pathway in tumors of endocrine tissues

Frontiers in Endocrinology

Volumn 6, Issue JAN, 2016, Pages

  Robbins, Helen Louise ^a   Hague, Angela ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adrenocortical carcinoma; Akt PKB kinases; Gastroenteropancreatic neuroendocrine tumors; Neuroblastoma; Parathyroid tumors; Phaeochromocytoma; Pituitary tumors; Thyroid tumors

Indexed keywords

B RAF KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADRENAL CORTEX CARCINOMA; ADRENAL MEDULLA TUMOR; COWDEN SYNDROME; DISEASE FREE SURVIVAL; ENDOCRINE TUMOR; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HYPOPHYSIS TUMOR; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PARAGANGLIOMA; PARATHYROID CARCINOMA; PHEOCHROMOCYTOMA; PROTEIN DEPHOSPHORYLATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOMA; TRANSCRIPTION REGULATION;

EID: 84962545496     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00188     Document Type: Review

References (190)

1. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 13:140-56. doi:10.1038/nrd4204
2. Saji M, Vasko V, Kada F, Allbritton EH, Burman KD, Ringel MD. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun (2005) 332:167-73. doi:10.1016/j.bbrc.2005.04.109
3. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell (2007) 129:1261-74. doi:10.1016/j.cell.2007.06.009
4. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal (2011) 23:1515-27. doi:10.1016/j.cellsig.2011.05.004
5. Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, et al. The emerging multiple roles of nuclear Akt. Biochim Biophys Acta (2012) 1823:2168-78. doi:10.1016/j.bbamcr.2012.08.017
6. Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, et al. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One (2014) 9:e95219. doi:10.1371/journal.pone.0095219
7. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 8:627-44. doi:10.1038/nrd2926
8. Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol (2014) 54:537-58. doi:10.1146/annurev-pharmtox-011112-140338
9. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 5:2881-911. doi:10.18632/oncotarget.2037
10. Karger S, Weidinger C, Krause K, Sheu SY, Aigner T, Gimm O, et al. FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer (2009) 16:189-99. doi:10.1677/ERC-07-0283
11. Weidinger C, Karger S, Krause K, Schierle K, Steinert F, Gimm O, et al. Distinct regulation of intrinsic apoptosis in benign and malignant thyroid tumours. Horm Metab Res (2010) 42:553-6. doi:10.1055/s-0030-1253374
12. Mahajan K, Mahajan NP. PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol (2012) 227:3178-84. doi:10.1002/jcp.24065
13. Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature (2014) 508:541-5. doi:10.1038/nature13079
14. Nitsche C, Edderkaoui M, Moore RM, Eibl G, Kasahara N, Treger J, et al. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2012) 142(377-387):e371-5. doi:10.1053/j.gastro.2011.10.026
15. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta (2011) 1813:1938-45. doi:10.1016/j.bbamcr.2011.06.002
16. Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book (2013). doi:10.1200/EdBook_AM.2013.33.e395
17. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell (2007) 12:487-502. doi:10.1016/j.devcel.2007.03.020
18. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 66:1500-8. doi:10.1158/0008-5472.CAN-05-2925
19. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2007) 26:1932-40. doi:10.1038/sj.onc.1209990
20. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer (2011) 117:4141-54. doi:10.1002/cncr.26011
21. Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther (2014) 13:2477-88. doi:10.1158/1535-7163.MCT-14-0330
22. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell (2007) 12:9-22. doi:10.1016/j.ccr.2007.05.008
23. Shtilbans V, Wu M, Burstein DE. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol (2008) 12:153-60. doi:10.1016/j.anndiagpath.2007.12.001
24. Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol (2003) 163:1687-98. doi:10.1016/S0002-9440(10)63525-0
25. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'Hern R, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res (2010) 12:R76. doi:10.1186/bcr2719
26. Yang ZY, Di MY, Yuan JQ, Shen WX, Zheng DY, Chen JZ, et al. The prognostic value of phosphorylated Akt in breast cancer: a systematic review. Sci Rep (2015) 5:7758. doi:10.1038/srep07758
27. Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr, Douglas WG, Anderson GR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck (2003) 25:662-70. doi:10.1002/hed.10277
28. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab (2011) 96:E2063-71. doi:10.1210/jc.2011-1616
29. Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL, et al. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet (2013) 92:76-80. doi:10.1016/j.ajhg.2012.10.021
30. The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 159:676-90. doi:10.1016/j.cell.2014.09.050
31. Forbes SA, Beare D, Gunasekaren P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucl Acids Res (2015) 43(21):D805-11. doi:10.1093/nar/gku1075
32. COSMIC, 2014. Catalogue of Somatic Mutations in Cancer. Wellcome Trust Sanger Institute (2013). Accessed: December 2015. Available at: www.sanger.ac.uk/cosmic
33. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 69:4885-93. doi:10.1158/0008-5472.CAN-09-0727
34. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/-mice. Genes Dev (2006) 20:1569-74. doi:10.1101/gad.1395006
35. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res (2007) 67:959-66. doi:10.1158/0008-5472.CAN-06-3524
36. Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell (2011) 20:173-86. doi:10.1016/j.ccr.2011.07.013
37. Kato Y, Ying H, Willingham MC, Cheng SY. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis. Endocrinology (2004) 145:4430-8. doi:10.1210/en.2004-0612
38. Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology (2005) 146:4456-63. doi:10.1210/en.2005-0172
39. Pringle DR, Vasko VV, Yu L, Manchanda PK, Lee AA, Zhang X, et al. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. J Clin Endocrinol Metab (2014) 99:E804-12. doi:10.1210/jc.2013-3101
40. Kemmochi S, Fujimoto H, Woo GH, Inoue K, Takahashi M, Mitsumori K, et al. Involvement of PTEN/Akt signaling in capsular invasive carcinomas developed in a rat two-stage thyroid carcinogenesis model after promotion with sulfadimethoxine. J Cancer Res Clin Oncol (2011) 137:723-32. doi:10.1007/s00432-010-0931-7
41. Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol (2010) 321:20-8. doi:10.1016/j.mce.2009.10.016
42. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res (2001) 61:6105-11.
43. Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J (2003) 50:77-83. doi:10.1507/endocrj.50.77
44. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer (2005) 92:1899-905. doi:10.1038/sj.bjc.6602595
45. Krzeslak A, Pomorski L, Lipinska A. Expression, localization, and phosphorylation of Akt1 in benign and malignant thyroid lesions. Endocr Pathol (2011) 22:206-11. doi:10.1007/s12022-011-9177-4
46. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene (2000) 19:3146-55. doi:10.1038/sj.onc.1203633
47. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 156:1693-700. doi:10.1016/S0002-9440(10)65040-7
48. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet (2004) 41:161-70. doi:10.1136/jmg.2003.015339
49. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res (2005) 65:10199-207. doi:10.1158/0008-5472.CAN-04-4259
50. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg (2007) 204:764-73. doi:10.1016/j.jamcollsurg.2006.12.037
51. Shin E, Hong SW, Kim SH, Yang WI. Expression of down stream molecules of RET (p-ERK, p-p38 MAPK, p-JNK and p-AKT) in papillary thyroid carcinomas. Yonsei Med J (2004) 45:306-13. doi:10.3349/ymj.2004.45.2.306
52. Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol (2005) 166:737-49. doi:10.1016/S0002-9440(10)62295-X
53. Jensen K, Patel A, Klubo-Gwiezdzinska J, Bauer A, Vasko V. Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis. Endocr Relat Cancer (2011) 18:613-26. doi:10.1530/ERC-10-0289
54. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, et al. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol (2007) 213:190-9. doi:10.1002/path.2215
55. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 93:3106-16. doi:10.1210/jc.2008-0273
56. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab (2008) 93:278-84. doi:10.1210/jc.2007-1076
57. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab (2008) 93:4088-97. doi:10.1210/jc.2008-0503
58. Liu J, Brown RE. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation. Ann Clin Lab Sci (2010) 40:211-7.
59. Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, et al. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol (2010) 21:90-100. doi:10.1007/s12022-010-9112-0
60. Zafón C, Castellvi J, Obiols G. Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis. Endocrinol Nutr (2010) 57:165-9. doi:10.1016/j.endonu.2010.02.005
61. Liu J, Brown RE. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants. Mod Pathol (2011) 24:1553-9. doi:10.1038/modpathol.2011.121
62. Ahmed M, Hussain AR, Bavi P, Ahmed SO, Al Sobhi SS, Al-Dayel F, et al. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis (2014) 35:1564-72. doi:10.1093/carcin/bgu051
63. Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, et al. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res (2014) 164:411-23. doi:10.1016/j.trsl.2014.06.005
64. Moraitis D, Karanikou M, Liakou C, Dimas K, Tzimas G, Tseleni-Balafouta S, et al. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas. Surgery (2014) 156:1542-8. doi:10.1016/j.surg.2014.08.095
65. Hussain AR, Bu R, Ahmed M, Jehan Z, Beg S, Al-Sobhi S, et al. Role of X-linked inhibitor of apoptosis as a prognostic marker and therapeutic target in papillary thyroid carcinoma. J Clin Endocrinol Metab (2015) 100:E974-84. doi:10.1210/jc.2014-4356
66. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M, et al. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab (2011) 96:2146-53. doi:10.1210/jc.2010-2655
67. Erovic BM, Kim D, Cassol C, Goldstein DP, Irish JC, Asa SL, et al. Prognostic and predictive markers in medullary thyroid carcinoma. Endocr Pathol (2012) 23:232-42. doi:10.1007/s12022-012-9225-8
68. Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res (2012) 18:3532-40. doi:10.1158/1078-0432.CCR-11-2700
69. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 37:375-87. doi:10.1016/j.ecl.2008.01.001
70. Romei C, Elisei R. RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol (2012) 3:54. doi:10.3389/fendo.2012.00054
71. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem (2000) 275:3568-76. doi:10.1074/jbc.275.5.3568
72. O'Malley Y, Lal G, Howe JR, Weigel RJ, Komorowski RA, Shilyansky J, et al. Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt. Surgery (2012) 152:1218-24. doi:10.1016/j.surg.2012.08.041
73. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 15:1340-50. doi:10.1038/ncb2860
74. Pitt SC, Chen H. The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery (2008) 144:721-4. doi:10.1016/j.surg.2008.06.028
75. Pennelli G, Galuppini F, Barollo S, Cavedon E, Bertazza L, Fassan M, et al. The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Hum Pathol (2015) 46:50-7. doi:10.1016/j.humpath.2014.09.006
76. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid carcinoma. J Bone Miner Res (2008) 23:1869-80. doi:10.1359/jbmr.081018
77. Erovic BM, Harris L, Jamali M, Goldstein DP, Irish JC, Asa SL, et al. Biomarkers of parathyroid carcinoma. Endocr Pathol (2012) 23:221-31. doi:10.1007/s12022-012-9222-y
78. Kasaian K, Wiseman SM, Thiessen N, Mungall KL, Corbett RD, Qian JQ, et al. Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J Pathol (2013) 230:249-60. doi:10.1002/path.4203
79. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer (2005) 12:423-33. doi:10.1677/erc.1.00949
80. Iino K, Oki Y, Yamashita M, Matsushita F, Hayashi C, Yogo K, et al. Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab (2010) 95:4003-11. doi:10.1210/jc.2009-2716
81. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ. Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab (2009) 94:4406-13. doi:10.1210/jc.2009-0471
82. Trovato M, Torre ML, Ragonese M, Simone A, Scarfi R, Barresi V, et al. /c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. Endocrine (2013) 44:735-43. doi:10.1007/s12020-013-9950-x
83. Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, et al. AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. J Clin Endocrinol Metab (2005) 90:4366-70. doi:10.1210/jc.2004-2198
84. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab (2009) 94:204-12. doi:10.1210/jc.2008-1456
85. Ronchi CL, Sbiera S, Leich E, Tissier F, Steinhauer S, Deutschbein T, et al. Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. J Clin Endocrinol Metab (2012) 97:E2251-60. doi:10.1210/jc.2012-2669
86. Hermsen IG, Haak HR, de Krijger RR, Kerkhofs TM, Feelders RA, de Herder WW, et al. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma. Eur J Endocrinol (2013) 169:51-8. doi:10.1530/EJE-13-0093
87. Qiao J, Kang JH, Cree J, Evers BM, Chung DH. Ets1 transcription factor mediates gastrin-releasing peptide-induced IL-8 regulation in neuroblastoma cells. Neoplasia (2007) 9:184-91. doi:10.1593/neo.06841
88. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res (2007) 67:735-45. doi:10.1158/0008-5472.CAN-06-2201
89. Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene (2008) 27:2910-22. doi:10.1038/sj.onc.1210938
90. Sartelet H, Ohta S, Barrette S, Rougemont AL, Brevet M, Regairaz M, et al. High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma. Histopathology (2010) 56:607-16. doi:10.1111/j.1365-2559.2010.03522.x
91. Sartelet H, Rougemont AL, Fabre M, Castaing M, Duval M, Fetni R, et al. Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Hum Pathol (2011) 42:1727-39. doi:10.1016/j.humpath.2011.01.019
92. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, Duval M, et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology (2012) 60:1144-55. doi:10.1111/j.1365-2559.2012.04191.x
93. Chaux A, Brimo F, Gonzalez-Roibon N, Shah S, Schultz L, Rizk JM, et al. Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas. Urology (2012) 80:.e7-12. doi:10.1016/j.urology.2012.04.032
94. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol (2006) 18:355-60. doi:10.1111/j.1365-2826.2006.01425.x
95. Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L, Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res (2010) 30:5063-7.
96. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol (2010) 65:889-93. doi:10.1007/s00280-009-1094-6
97. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 18:1777-89. doi:10.1158/1078-0432.CCR-11-2123
98. Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, et al. Prognostic significance of MTOR pathway component expression in neuroendocrine tumors. J Clin Oncol (2013) 31:3418-25. doi:10.1200/JCO.2012.46.6946
99. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer (2001) 8:287-305. doi:10.1677/erc.0.0080287
100. Vender JR, Laird MD, Dhandapani KM. Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery (2008) 62:1122-7. doi:10.1227/01.neu.0000325874.82999.75
101. Xu M, Shorts-Cary L, Knox AJ, Kleinsmidt-DeMasters B, Lillehei K, Wierman ME. Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: role in proliferation and survival. Endocrinology (2009) 150:2064-71. doi:10.1210/en.2008-1265
102. Lu C, Willingham MC, Furuya F, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology (2008) 149:3339-45. doi:10.1210/en.2007-1696
103. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A (2006) 103:15558-63. doi:10.1073/pnas.0603877103
104. Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, Pellegata NS. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol Cancer Ther (2011) 10:1450-9. doi:10.1158/1535-7163.MCT-11-0188
105. Lee M, Wiedemann T, Gross C, Leinhauser I, Roncaroli F, Braren R, et al. Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin Cancer Res (2015) 21:3204-15. doi:10.1158/1078-0432.CCR-15-0288
106. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer (2009) 16:301-10. doi:10.1677/ERC-08-0167
107. Murat CB, Braga PB, Fortes MA, Bronstein MD, Correa-Giannella ML, Giorgi RR. Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. Braz J Med Biol Res (2012) 45:851-5. doi:10.1590/S0100-879X2012007500115
108. Monsalves E, Juraschka K, Tateno T, Agnihotri S, Asa SL, Ezzat S, et al. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer (2014) 21:R331-44. doi:10.1530/ERC-14-0188
109. Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, Stratakis CA. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene (2013) 32:1651-9. doi:10.1038/onc.2012.190
110. Sajjad EA, Zielinski G, Maksymowicz M, Hutnik L, Bednarczuk T, Wlodarski P. mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. Endocr Pathol (2013) 24:11-9. doi:10.1007/s12022-012-9230-y
111. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res (1999) 5:2133-9.
112. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer (2009) 16:1329-38. doi:10.1677/ERC-09-0101
113. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab (2010) 95:968-76. doi:10.1210/jc.2009-1641
114. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res (2010) 70:666-74. doi:10.1158/0008-5472.CAN-09-2951
115. Sukumari-Ramesh S, Singh N, Dhandapani KM, Vender JR. mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation. Surg Neurol Int (2011) 2:22. doi:10.4103/2152-7806.77029
116. Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, et al. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology (2013) 154:1247-59. doi:10.1210/en.2012-1908
117. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, et al. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary (2012) 15:37-43. doi:10.1007/s11102-011-0341-0
118. Mazzuco TL, Durand J, Chapman A, Crespigio J, Bourdeau I. Genetic aspects of adrenocortical tumours and hyperplasias. Clin Endocrinol (2012) 77:1-10. doi:10.1111/j.1365-2265.2012.04403.x
119. Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. Br J Surg (2015) 102:291-306. doi:10.1002/bjs.9743
120. Ragazzon B, Assie G, Bertherat J. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer (2011) 18:R15-27. doi:10.1530/ERC-10-0220
121. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2010) 65:765-73. doi:10.1007/s00280-009-1083-9
122. Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer (2014) 5:232-9. doi:10.1007/s12672-014-0182-1
123. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol (2015) 16:426-35. doi:10.1016/S1470-2045(15)70081-1
124. Zhang X, Wang X, Qin L, Xu T, Zhu Z, Zhong S, et al. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology (2015) 85(273):e271-7. doi:10.1016/j.urology.2014.09.020
125. Sasano H, Satoh F, Nakamura Y. Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma. Endocr Pathol (2014) 25:366-70. doi:10.1007/s12022-014-9334-7
126. Salomon A, Keramidas M, Maisin C, Thomas M. Loss of beta-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition. Oncotarget (2015). doi:10.18632/oncotarget.3222
127. Rubin B, Monticelli H, Redaelli M, Mucignat C, Barollo S, Bertazza L, et al. Mitogen-activated protein kinase pathway: genetic analysis of 95 adrenocortical tumors. Cancer Invest (2015):1-6. doi:10.3109/07357907.2015.1080832
128. Nakamura M, Miki Y, Akahira J, Morimoto R, Satoh F, Ishidoya S, et al. An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol (2009) 20:17-23. doi:10.1007/s12022-009-9058-2
129. De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, Waaijers M, Lamberts SW, et al. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr Relat Cancer (2012) 19:351-64. doi:10.1530/ERC-11-0270
130. Mariniello B, Rosato A, Zuccolotto G, Rubin B, Cicala MV, Finco I, et al. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer (2012) 19:527-39. doi:10.1530/ERC-11-0337
131. Doghman M, Lalli E. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Mol Cell Endocrinol (2012) 364:101-4. doi:10.1016/j.mce.2012.08.014
132. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 108:826-30. doi:10.1038/bjc.2013.46
133. Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM. The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology (2014) 83:1225-32. doi:10.1016/j.urology.2014.01.007
134. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 11:423-36. doi:10.1677/erc.1.00829
135. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res (2009) 41:697-702. doi:10.1055/s-0029-1220687
136. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science (1995) 267:2003-6. doi:10.1126/science.7701324
137. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 275:661-5. doi:10.1126/science.275.5300.661
138. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem (2001) 276:22368-74. doi:10.1074/jbc.M011688200
139. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells. World J Surg (2009) 33:2452-7. doi:10.1007/s00268-009-0175-3
140. Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke ST, Martiniova L, et al. ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle (2007) 6:1946-50. doi:10.4161/cc.6.15.4521
141. Lee M, Waser B, Reubi JC, Pellegata NS. Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway. Mol Endocrinol (2012) 26:1394-405. doi:10.1210/me.2012-1055
142. Leinhauser I, Richter A, Lee M, Hofig I, Anastasov N, Fend F, et al. Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget (2015) 17:39111-26. doi:10.18632/oncotarget.4912
143. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet (2010) 42:229-33. doi:10.1038/ng.533
144. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 304:2611-9. doi:10.1001/jama.2010.1830
145. Giubellino A, Bullova P, Nolting S, Turkova H, Powers JF, Liu Q, et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology (2013) 154:646-55. doi:10.1210/en.2012-1854
146. Saito Y, Tanaka Y, Aita Y, Ishii KA, Ikeda T, Isobe K, et al. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab (2012) 302:E615-25. doi:10.1152/ajpendo.00035.2011
147. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med (2015) 66:49-63. doi:10.1146/annurev-med-011514-023121
148. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 3:203-16. doi:10.1038/nrc1014
149. Maris JM. Recent advances in neuroblastoma. N Engl J Med (2010) 362:2202-11. doi:10.1056/NEJMra0804577
150. Liu L, Brown JC III, Webster WW, Morrisett RA, Monaghan DT. Insulin potentiates N-methyl-D-aspartate receptor activity in Xenopus oocytes and rat hippocampus. Neurosci Lett (1995) 192:5-8. doi:10.1016/0304-3940(95)11593-L
151. Li Z, Jaboin J, Dennis PA, Thiele CJ. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res (2005) 65:2070-5. doi:10.1158/0008-5472.CAN-04-3606
152. Bender A, Opel D, Naumann I, Kappler R, Friedman L, von Schweinitz D, et al. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene (2011) 30:494-503. doi:10.1038/onc.2010.429
153. Qiao J, Lee S, Paul P, Qiao L, Taylor CJ, Schlegel C, et al. Akt2 regulates metastatic potential in neuroblastoma. PLoS One (2013) 8:e56382. doi:10.1371/journal.pone.0056382
154. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 66:8139-46. doi:10.1158/0008-5472.CAN-05-2769
155. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer (2010) 9:83. doi:10.1186/1476-4598-9-83
156. Qiao J, Kang J, Cree J, Evers BM, Chung DH. Gastrin-releasing peptide-induced down-regulation of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome ten) in neuroblastomas. Ann Surg (2005) 241:684-91. doi:10.1097/01.sla.0000161173.47717.71
157. Izycka-Swieszewska E, Drozynska E, Rzepko R, Kobierska-Gulida G, Grajkowska W, Perek D, et al. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol J Pathol (2010) 61:192-8.
158. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene (2011) 30:97-105. doi:10.1038/onc.2010.383
159. Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res (2013) 73:2189-98. doi:10.1158/0008-5472.CAN-12-3767
160. Oberg K, Knigge U, Kwekkeboom D, Perren A, Group EGW. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 23(Suppl 7):vii124-30. doi:10.1093/annonc/mds267
161. Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge N. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer (2014) 21:R153-63. doi:10.1530/ERC-13-0125
162. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 26:3063-72. doi:10.1200/JCO.2007.15.4377
163. Pitt SC, Chen H, Kunnimalaiyaan M. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol (2009) 16:2936-42. doi:10.1245/s10434-009-0591-5
164. Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, et al. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol (2012) 40:1659-67. doi:10.3892/ijo.2012.1328
165. Zitzmann K, Vlotides G, Brand S, Lahm H, Spottl G, Goke B, et al. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr Relat Cancer (2012) 19:423-34. doi:10.1530/ERC-12-0074
166. Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs (2013) 24:66-72. doi:10.1097/CAD.0b013e3283584f75
167. Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer (2011) 128:1045-56. doi:10.1002/ijc.25441
168. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol (2010) 28:245-55. doi:10.1200/JCO.2008.21.5988
169. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 157:1097-103. doi:10.1016/S0002-9440(10)64624-X
170. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 331:1199-203. doi:10.1126/science.1200609
171. Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 123:2502-8. doi:10.1172/JCI67963
172. O'Toole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P, et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer (2010) 17:847-56. doi:10.1677/ERC-09-0204
173. Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, et al. Progesterone receptor and PTEN expression predict survival in patients with low-and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med (2014) 138:1027-36. doi:10.5858/arpa.2013-0195-OA
174. Guo SS, Wu X, Shimoide AT, Wong J, Moatamed F, Sawicki MP. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol (2003) 179:73-9. doi:10.1677/joe.0.1790073
175. Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer (2011) 18:181-92. doi:10.1677/ERC-10-0126
176. Zhou CF, Ji J, Yuan F, Shi M, Zhang J, Liu BY, et al. mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepatogastroenterology (2011) 58:2140-3. doi:10.5754/hge11212
177. Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett (2013) 335:1-8. doi:10.1016/j.canlet.2013.02.016
178. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 364:514-23. doi:10.1056/NEJMoa1009290
179. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 29:4688-95. doi:10.1200/JCO.2011.35.5263
180. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res (2005) 11:4338-40. doi:10.1158/1078-0432.CCR-05-0422
181. Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, Pawade J, et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer (2011) 104:1755-61. doi:10.1038/bjc.2011.132
182. Khor TO, Gul YA, Ithnin H, Seow HF. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma. Cancer Lett (2004) 210:139-50. doi:10.1016/j.canlet.2004.01.017
183. Risso G, Blaustein M, Pozzi B, Mammi P, Srebrow A. Akt/PKB: one kinase, many modifications. Biochem J (2015) 468:203-14. doi:10.1042/BJ20150041
184. Lin CH, Liu SY, Lee EH. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1. Oncogene (2015). doi:10.1038/onc.2015.115
185. Kang ES, Han D, Park J, Kwak TK, Oh MA, Lee SA, et al. GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic beta cells. Exp Cell Res (2008) 314:2238-48. doi:10.1016/j.yexcr.2008.04.014
186. Yi H, Long B, Ye X, Zhang L, Liu X, Zhang C. Autophagy: a potential target for thyroid cancer therapy (review). Mol Clin Oncol (2014) 2:661-5.
187. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res (2013) 37:1461-7. doi:10.1016/j.leukres.2013.07.034
188. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res (2013) 19:6976-86. doi:10.1158/1078-0432.CCR-13-0978
189. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res (2014) 20:3870-83. doi:10.1158/1078-0432.CCR-13-1507
190. Gundisch S, Annaratone L, Beese C, Drecol E, Marchio C, Quaglino E, et al. Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. Lab Invest (2015) 95:561-71. doi:10.1038/labinvest.2015.37